Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors-Reference-Cited by-同舟云学术

Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors

Published:2016-09 Issue:3 Volume:90 Page:638-647
ISSN:0085-2538
Container-title:Kidney International
language:en
Short-container-title:Kidney International

Author:

Cortazar Frank B.,Marrone Kristen A.,Troxell Megan L.,Ralto Kenneth M.,Hoenig Melanie P.,Brahmer Julie R.,Le Dung T.,Lipson Evan J.,Glezerman Ilya G.,Wolchok Jedd,Cornell Lynn D.,Feldman Paul,Stokes Michael B.,Zapata Sarah A.,Hodi F. Stephen,Ott Patrick A.,Yamashita Michifumi,Leaf David E.

Publisher

Elsevier BV

Subject

Nephrology

Reference33 articles.

1. Immune checkpoint blockade in cancer therapy;Postow;J Clin Oncol,2015

2. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells;Krummel;J Exp Med,1996

3. Negative regulation of T-cell function by PD-1;Zha;Crit Rev Immunol,2004

4. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial;Ribas;Lancet Oncol,2015

5. Improved survival with ipilimumab in patients with metastatic melanoma;Hodi;N Engl J Med,2010

Cited by 538 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Single-cell RNA sequencing analysis of peripheral blood mononuclear cells in PD-1-induced renal toxicity in patients with lung cancer;BMC Nephrology;2024-09-14

2. Natural polysaccharides as promising reno-protective agents for the treatment of various kidney injury;Pharmacological Research;2024-09

3. Renal Immune-Related Adverse Event Difficult to Diagnose during Nivolumab Treatment for Hypopharyngeal Carcinoma: Case Report;Case Reports in Oncology;2024-08-30

4. Immune checkpoint inhibitor–associated nephritis—treatment standard;Nephrology Dialysis Transplantation;2024-08-13

5. Clinical features associated with immune checkpoint inhibitor nephritis: a single-center clinical case series;Cancer Immunology, Immunotherapy;2024-08-06